PMID- 37834968
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231020
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 12
IP  - 19
DP  - 2023 Sep 30
TI  - Possible New Histological Prognostic Index for Large B-Cell Lymphoma.
LID - 10.3390/jcm12196324 [doi]
LID - 6324
AB  - We conducted a retrospective analysis of GRP94 immunohistochemical (IHC) 
      staining, an ER stress protein, on large B-cell lymphoma (LBCL) cells, 
      intracellular p53, and 15 factors involved in the metabolism of the CHOP regimen: 
      AKR1C3 (HO metabolism), CYP3A4 (CHOP metabolism), and HO efflux pumps (MDR1 and 
      MRP1). The study subjects were 42 patients with LBCL at our hospital. The IHC 
      staining used antibodies against the 17 factors. The odds ratios by logistic 
      regression analysis used a dichotomous variable of CR and non-CR/relapse were 
      statistically significant for MDR1, MRP1, and AKR1C3. The overall survival (OS) 
      after R-CHOP was compared by the log-rank test. The four groups showed that Very 
      good (5-year OS, 100%) consisted of four patients who showed negative IHC 
      staining for both GRP94 and CYP3A4. Very poor (1-year OS, 0%) consisted of three 
      patients who showed positive results in IHC for both GRP94 and CYP3A4. The 
      remaining 35 patients comprised two subgroups: Good (5-year OS 60-80%): 15 
      patients who showed negative staining for both MDR1 and AKR1C3 and Poor (5-year 
      OS, 10-20%): 20 patients who showed positive staining for either MDR, AKR1C3, 
      MRP1, or p53. The Histological Prognostic Index (HPI) (the four groups: Very 
      poor, Poor, Good, and Very good) is a breakthrough method for stratifying 
      patients based on the factors involved in the development of treatment 
      resistance.
FAU - Nitta, Hideaki
AU  - Nitta H
AUID- ORCID: 0000-0002-1209-6594
AD  - Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, 
      Urayasu-shi 279-0021, Japan.
FAU - Takizawa, Haruko
AU  - Takizawa H
AD  - Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, 
      Urayasu-shi 279-0021, Japan.
FAU - Mitsumori, Toru
AU  - Mitsumori T
AD  - Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, 
      Urayasu-shi 279-0021, Japan.
FAU - Iizuka-Honma, Hiroko
AU  - Iizuka-Honma H
AD  - Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, 
      Urayasu-shi 279-0021, Japan.
FAU - Araki, Yoshihiko
AU  - Araki Y
AUID- ORCID: 0000-0002-4759-9765
AD  - Department of Pathology and Microbiology, Division of Microbiology, Nihon 
      University School of Medicine, Itabashi-ku, Tokyo 173-8610, Japan.
FAU - Fujishiro, Maki
AU  - Fujishiro M
AD  - Institute for Environmental and Gender-Specific Medicine, Juntendo University 
      Urayasu Hospital, Chiba 279-0021, Japan.
FAU - Tomita, Shigeki
AU  - Tomita S
AD  - Department of Diagnostic Pathology, Juntendo University Urayasu Hospital, Chiba 
      279-0021, Japan.
FAU - Kishikawa, Satsuki
AU  - Kishikawa S
AD  - Department of Diagnostic Pathology, Juntendo University Urayasu Hospital, Chiba 
      279-0021, Japan.
FAU - Hashizume, Akane
AU  - Hashizume A
AD  - Department of Diagnostic Pathology, Juntendo University Urayasu Hospital, Chiba 
      279-0021, Japan.
FAU - Sawada, Tomohiro
AU  - Sawada T
AD  - Department of Clinical Laboratory, Juntendo University Urayasu Hospital, Chiba 
      279-0021, Japan.
FAU - Okubo, Mitsuo
AU  - Okubo M
AD  - Laboratory of Blood Transfusion, Juntendo University Urayasu Hospital, Chiba 
      279-0021, Japan.
FAU - Sekiguchi, Yasunobu
AU  - Sekiguchi Y
AD  - Hematology Clinic, Saitama Cancer Center, Saitama 362-0806, Japan.
FAU - Ando, Miki
AU  - Ando M
AD  - Division of Hematology, Juntendo University Juntendo Hospital, 3-1-3 Hongo, 
      Bunkyo-ku, Tokyo 113-0033, Japan.
FAU - Noguchi, Masaaki
AU  - Noguchi M
AD  - Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, 
      Urayasu-shi 279-0021, Japan.
LA  - eng
PT  - Case Reports
DEP - 20230930
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10573887
OTO - NOTNLM
OT  - CYP3A4
OT  - P53
OT  - aldo-keto reductase family 1 member C3 (AKR1C3)
OT  - glucose-regulated protein 94 (GRP94)
OT  - immunohistochemical (IHC) staining
OT  - large B-cell lymphoma (LBCL)
OT  - multidrug resistance protein 1 (MDR1)
OT  - multidrug resistance-associated protein 1 (MRP1)
COIS- The authors declare no conflict of interest.
EDAT- 2023/10/14 10:45
MHDA- 2023/10/14 10:46
PMCR- 2023/09/30
CRDT- 2023/10/14 01:08
PHST- 2023/08/16 00:00 [received]
PHST- 2023/09/21 00:00 [revised]
PHST- 2023/09/26 00:00 [accepted]
PHST- 2023/10/14 10:46 [medline]
PHST- 2023/10/14 10:45 [pubmed]
PHST- 2023/10/14 01:08 [entrez]
PHST- 2023/09/30 00:00 [pmc-release]
AID - jcm12196324 [pii]
AID - jcm-12-06324 [pii]
AID - 10.3390/jcm12196324 [doi]
PST - epublish
SO  - J Clin Med. 2023 Sep 30;12(19):6324. doi: 10.3390/jcm12196324.